| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Outline of Final Research Achievements |
We carried out translational research projects based on the nanoparticle-mediated drug delivery system and PPAR-gamma agonists to develop a novel Nano-medicine for cardiovascular diseases.
In a mouse model of plaque rupture, PPAR-gamma nano-medicine stabilized atherosclerotic plaques, through a reduction in the number of Ly6C inflammatory monocytes in the peripheral blood and M1 inflammatory macrophage and an increase in M2 macrophage in the aortic tissue.
In a mouse model of myocardial ischemia-reperfusion (IR) injury, PPAR-gamma nano-medicine inhibited monocyte recruitment to IR heart and reduced infarct size.
|
